Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Cabinet Ministers In Stalemate Over New Pharma Policy

This article was originally published in PharmAsia News

Executive Summary

Three Indian Cabinet ministers responsible for reaching a compromise on the country's drug policy are stalemated. The health and chemicals ministries, led by the agriculture minister, were assigned to sort out the policy. The health ministry wants quality control and drug supplies to be excluded from the policy. The chemicals ministry, which has administrative authority over pharmas, drafted the policy, but quality regulation and marketing approvals are under the purview of the health ministry. The agriculture minister told both sides to work out their differences. (Click here for more

You may also be interested in...



QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel